CommercialCoverageMedium impact
ELIQUIS® (apixaban) Returned to Preferred Formulary Status
CareFirst BlueCross BlueShield·Cardiology, Internal Medicine, Family Medicine +3 more·Pharmacy
Effective date
Jul 1, 2022
We identified it
Jun 20, 2026
Summary
ELIQUIS® (apixaban) has been returned to preferred formulary status (Tier 2) for CareFirst Commercial Formularies effective July 1, 2022. This means patients can now access ELIQUIS without requiring a formulary exception request, making it easier to prescribe and bill for this anticoagulant medication.
Action Required
Immediately: Billing team should update prior authorization requirements for ELIQUIS® (apixaban) prescriptions for CareFirst Commercial members - formulary exceptions are no longer needed. Update billing software to reflect Tier 2 preferred status. Notify providers that ELIQUIS can now be prescribed without formulary exception requests for CareFirst Commercial patients.